Lim Ji Eun, Son Youngsook
1Department of Genetic Engineering, College of Life Science and Graduate School of Biotechnology, Kyung Hee University, 1732 Deogyeong-daero, Giheung-gu, Yongin-si, Gyeonggi-do 17104 Republic of Korea.
2Kyung Hee Institute of Regenerative Medicine, Kyung Hee University Hospital, 24 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02453 Republic of Korea.
Tissue Eng Regen Med. 2017 Nov 20;14(6):679-698. doi: 10.1007/s13770-017-0097-3. eCollection 2017 Dec.
In almost all human tissues and organs, adult stem cells or tissue stem cells are present in a unique location, the so-called stem cell niche or its equivalent, continuously replenishing functional differentiated cells. Those endogenous stem cells can be expanded for cell therapeutics using cell culture or recalled for tissue repair through cell trafficking and homing. In the aging process, inefficiency in the endogenous stem cell-mediated healing mechanism can emerge from a variety of impairments that accumulate in the processes of stem cell self-renewal, function, differentiation capacity, and trafficking through cell autonomous intrinsic pathways (such as epigenetic alterations) or systemic extrinsic pathways. This review examines the homeostasis of endogenous stem cells, particularly bone marrow stem cells, and their dysregulation in disease and aging and discusses possible intervention strategies. Several systemic pro-aging and rejuvenating factors, recognized in heterochronic parabiosis or premature aging progeroid animal models, are reviewed as possible anti-aging pharmaceutical targets from the perspective of a healthy environment for endogenous stem cells. A variety of epigenetic modifications and chromosome architectures are reviewed as an intrinsic cellular pathway for aging and senescence. A gradual increase in inflammatory burden during aging is also reviewed. Finally, the tissue repair and anti-aging effects of Substance-P, a peptide stimulating stem cell trafficking from the bone marrow and modifying the inflammatory response, are discussed as a future anti-aging target.
在几乎所有人体组织和器官中,成体干细胞或组织干细胞都存在于一个独特的位置,即所谓的干细胞生态位或其等效物中,不断补充功能性分化细胞。这些内源性干细胞可以通过细胞培养进行扩增以用于细胞治疗,或者通过细胞迁移和归巢被召回用于组织修复。在衰老过程中,内源性干细胞介导的愈合机制效率低下可能源于干细胞自我更新、功能、分化能力以及通过细胞自主内在途径(如表观遗传改变)或全身外在途径进行迁移过程中积累的各种损伤。本综述探讨了内源性干细胞,特别是骨髓干细胞的稳态,以及它们在疾病和衰老中的失调,并讨论了可能的干预策略。从为内源性干细胞提供健康环境的角度,对异时联体共生或早衰类早衰动物模型中识别出的几种全身促衰老和促年轻化因子进行了综述,作为可能的抗衰老药物靶点。对各种表观遗传修饰和染色体结构进行了综述,作为衰老和衰老的内在细胞途径。还综述了衰老过程中炎症负担的逐渐增加。最后,讨论了P物质(一种刺激骨髓干细胞迁移并调节炎症反应的肽)的组织修复和抗衰老作用,作为未来的抗衰老靶点。